EpiCept Jumps on European Marketing Approval

Oct.10.06 | About: EpiCept Corporation (EPCT)

EpiCept Corporation (OTC:EPCT) announced late on Monday it had sent a Market Authorization Application [MAA] with the European Medicines Agency for the approval of Ceplene.

Ceplene is EpiCept's lead oncology product that is administered with Interleukin-2 for first remission in Acute Myeloid Leukemia patients.

The odds look good for approval as the European Agency had already designated Ceplene Orphan Drug Status, and phase 3 results had met critical endpoints.

CEO Talley believes the market potential for Ceplene in the European Union alone can exceed $300 million.

Shares of EpiCept were already up 18% in pre-market trading.